Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. METHODS: Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. RESULTS: The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). CONCLUSIONS: Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [31]
In the citing paper
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [57]
In the citing paper
“A randomized study comparing lenalidomide and dexamethasone to melphalan, thalidomide and prednisone in newly diagnosed patients demonstrated superior 4-year OS (59% versus 51%; HR 0.78, p=0.02) and led to FDA approval in 201527.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“For older patients and/or those unfit for autologous transplantation, the preferred induction approach remains lenalidomide in combination with dexamethasone with or without daratumumab, regimens that are effective and well tolerated in this patient population27,29.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“Thalidomide analogues often lead to peripheral blood cytopenias, most commonly neutropenia (28% grade 3/4) and thrombocytopenia (8% grade 3/4)27.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Self-citation
Cited by
Items 401–500 of 1,000
New generation drugs for treatment of multiple myeloma
Alanazi, F. G., Kwa, F. A. A., Burchall, G., & Jackson, D. E. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.008 · Cited by 43
Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents
Zagouri, F., Kastritis, E., Symeonidis, A. S., Giannakoulas, N. C., Katodritou, E., Delimpasi, S., Repousis, P., Terpos, E., Dimopoulos, M. A., & The Greek Myeloma Study Group (2013) · European Journal Of Haematology · doi:10.1111/ejh.12255 · Cited by 41
Self-citationActivity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
Gunther, A., Baumann, P., Burger, R., Kellner, C., Klapper, W., Schmidmaier, R., & Gramatzki, M. (2015) · Haematologica · doi:10.3324/haematol.2014.116269 · Cited by 42
Clinical trials with anti‐angiogenic agents in hematological malignancies
Medinger, M., & Mross, K. (2010) · Journal of Angiogenesis Research · doi:10.1186/2040-2384-2-10 · Cited by 40
“In 2 phase III trials lenalidomide in combination with dexamethasone, it showed remarkable response rates and better toxicity profile than thalidomide [96,97].”
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
Pomalidomide: New immunomodulatory agent with potent antiproliferative effects
Richardson, P. G. G., Mark, T. M., & Lacy, M. Q. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.02.001 · Cited by 44
Palumbo, A. P., Dimopoulos, M. A., Miguel, J. F. S., Harousseau, J., Attal, M., Hussein, M. A., Knop, S. T., Ludwig, H., von Lilienfeld‐Toal, M., & Sonneveld, P. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.07.003 · Cited by 41
Self-citationNovel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
Orlowski, R. Z. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.007 · Cited by 41
Rossi, A., Mark, T. M., Jayabalan, D. S., Christos, P. J., Zafar, F., Pekle, K. A., Pearse, R. N., Chen‐Kiang, S., Coleman, M., & Niesvizky, R. (2013) · Blood · doi:10.1182/blood-2012-08-448563 · Cited by 41
Neuber, B., Herth, I., Tolliver, C., Schönland, S. O., Hegenbart, U., Hose, D., Witzens‐Harig, M., Ho, A. D., Goldschmidt, H., Klein, B., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002460 · Cited by 39
New therapies in nonmuscle invasive bladder cancer treatment
Agarwal, P. K., Rayn, K. N., Hale, G. R., & Grave, G. P.-L. (2017) · Indian Journal of Urology · doi:10.4103/iju.iju_296_17 · Cited by 40
“Lenalidomide, an immunomodulator, is a thalidomide derivative with a known tumoricidal activity that has shown improved time to progression and increases in overall survival in relapsing multiple myeloma Phase III trials.[66,67] These properties make it an attractive potential treatment option for NMIBC, for which it…”
BackgroundNishimura, N., Radwan, M. O., Amano, M., Endo, S., Fujii, E., Hayashi, H., Ueno, S., Ueno, N., Tatetsu, H., Hata, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14154 · Cited by 41
Liu, W. M., Henry, J. Y., Meyer, B., Bartlett, J. B., Dalgleish, A. G., & Galustian, C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605206 · Cited by 43
“…is approved by the US Food and Drug Administration for use in patients with myelodysplastic syndromes (associated with no or 5q-deletions), and in combination with dexamethasone in patients with multiple myeloma who have received one previous therapy (Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundNovel approaches for reducing free light chains in patients with myeloma kidney
Hutchison, C. A., Bladé, J., Cockwell, P., Cook, M. A., Drayson, M. T., Fermand, J., Kastritis, E., Kyle, R. A., Leung, N., Pasquali, S., et al. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.14 · Cited by 39
“In the initial phase III trials comparing lenalidomide plus dexamethasone with dexamethasone plus placebo in patients with relapsed or refractory multiple myeloma, patients with a serum creatinine level of >221 μmol/l were generally excluded”
BackgroundModulating T regulatory cells in cancer: how close are we?
Banerjee, A., Vasanthakumar, A., & Grigoriadis, G. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.12 · Cited by 44
Emerging pathways as individualized therapeutic target of multiple myeloma
Misso, G., Zappavigna, S., Castellano, M., Rosa, G. D., Martino, M. T. D., Tagliaferri, P., Tassone, P., & Caraglia, M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.807338 · Cited by 41
“Currently, a number of Phase I and II trials are also exploring the combination of lenalidomide with other novel anti-MM agents [66,67].”
BackgroundChen, N., Kasserra, C., Reyes, J. F., Liu, L., & Lau, H. S. H. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1966-z · Cited by 43
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
Gorgun, G., Donk, V. D., Groen, Jakubikova, Mitsiades, C., Hideshima, T., Richardson, P., Nijhof, Raymakers, Lokhorst, H., et al. (2012) · Cancer Management and Research · doi:10.2147/cmar.s27087 · Cited by 38
Luo, J., Gagne, J. J., Landon, J. E., Avorn, J., & Kesselheim, A. S. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.018 · Cited by 38
CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
Barankiewicz, J., Salomon‐Perzyński, A., Misiewicz-Krzemińska, I., & Lech‐Marańda, E. (2022) · Cancers · doi:10.3390/cancers14184492 · Cited by 42
“For patients who have not previously been exposed to lenalidomide, RD alone (especially in frail patients) [52], or combined with carfilzomib (the ASPIRE trial) [53,54] ixazomib (the TOURMALINE trial) [55], daratumumab (the POLLUX trial) [56] or elotuzumab (the ELOQUENT-2 trial) [57,58] are highly relevant therapeutic…”
BackgroundClinical characteristics of patients with relapsed multiple myeloma
Dimopoulos, M. A., Terpos, E., Niesvizky, R., & Palumbo, A. P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.07.005 · Cited by 42
“Similar rates were reported in two phase III studies examining lenalidomide plus dexamethasone versus dexamethasone alone in relapsed patients: the MM-009 study patient population was 82.1% white and 11.9% black (enrolled from Europe, Israel, and Australia), while the MM-010 study patient population was 98.3% white an…”
InfluentialSelf-citationRöllig, C., & Illmer, T. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.04.007 · Cited by 38
Panobinostat for the treatment of multiple myeloma
Neri, P. E., Bahlis, N. J., & Lonial, S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.668883 · Cited by 39
“Although survival in this disease has improved recently with the availability of new classes of agents such as proteasome inhibitors and immunomodulatory agents [1,2], it remains incurable and new treatment options are urgently needed.”
BackgroundChang, H., Jiang, A., Qi, C. X. Y., Trieu, Y., Chen, C. I., & Reece, D. E. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.524325 · Cited by 39
“The phase 3 trials included very few patients who had previously received bortezomib, and did not detail the effect of prior exposure [3,4].”
BackgroundResultInfluentialLenalidomide: A new therapy for multiple myeloma
Palumbo, A. P., Miguel, J. F. S., Sonneveld, P., Moreau, P., Drach, J. W., Morgan, G. J., & Einsele, H. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.12.005 · Cited by 37
Self-citationMultiple Myeloma as a Model for the Role of Bone Marrow Niches in the Control of Angiogenesis
Ribatti, D., Nico, B., & Vacca, A. (2014) · International review of cytology · doi:10.1016/bs.ircmb.2014.10.004 · Cited by 41
Lund, T., Abildgaard, N., Andersen, T. L., Delaissé, J., & Plesner, T. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01417.x · Cited by 38
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Elbezanti, W. O., Challagundla, K. B., Jonnalagadda, S. C., Budak-Alpdoǧan, T., & Pandey, M. K. (2023) · Pharmaceuticals · doi:10.3390/ph16030415 · Cited by 39
“Lenalidomide 2006 Received one prior therapy neutropenia, thrombocytopenia, leukopenia, lymphopenia, febrile neutropenia, deep vein thrombosis, pulmonary embolism, atrial fibrillation, constipation, diarrhea, fatigue, pneumonia, hypokalemia, hypocalcemia, muscle weakness, neuropathy, and depression [50]”
BackgroundNovel agents and new therapeutic approaches for treatment of multiple myeloma
Ria, R., Reale, A., & Vacca, A. (2014) · World Journal of Methodology · doi:10.5662/wjm.v4.i2.73 · Cited by 40
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma
Efebera, Y. A., Qureshi, S., Cole, S., Saliba, R. M., Pelosini, M., Patel, R. M., Koca, E., Mendoza, F. L., Wang, M. L., Shah, J. J., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.02.015 · Cited by 39
“Despite this improvement, however, EFS in most patients with persistent or refractory disease is only 6-14 months [23-26].”
König, C., Kleber, M., Reinhardt, H., Knop, S. T., Wäsch, R., & Engelhardt, M. M. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1951-6 · Cited by 36
Fact or fiction - identifying the elusive multiple myeloma stem cell
Kellner, J. N., Liu, B., Kang, Y., & Li, Z. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-91 · Cited by 40
“Immunomodulatory agents, thalidomide and lenalidomide, both have had promising results in improving time to remission and survival in newly diagnosed and relapsed MM [68,69].”
Backgroundde la Rubia, J., Roig, M., Ibáñez, Á., García, I., Vera, J. A. E., Aguilar, C., Campo, R. D., González, N., Martínez, R., Palomera, L., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01500.x · Cited by 35
“Finally, among responding patients, median duration of response has not been reached, pointing that durability of response is also comparable to those of patients with MM with normal renal function in the relapsed setting (1, 2).”
BackgroundResultInfluentialRodon, P., Hulin, C., Pegourie, B., Tiab, M., Anglaret, B., Benboubker, L., Jardel, H., Decaux, O., Kolb, B., Roussel, M., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.110890 · Cited by 35
“Regarding high-risk cytogenetics, 7 of 9 patients with t(4;14) responded (2 CR, 4 VGPR and one PR); one progressed on therapy, and the last patient died during cycle 2 from infection.”
BackgroundMethodInfluentialTreating Multiple Myeloma Patients With Oral Therapies
Kumar, S. K., Vij, R., Noga, S. J., Berg, D. T., Brent, L. D., Dollar, L. E., & Chari, A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.024 · Cited by 37
“4% with dexamethasone.(12,31) However, prophylactic treatment with aspirin for patients at standard risk for VTEs, and low-molecular-weight heparin or adjusted-dose warfarin for high-risk patients has been shown to reduce the risk of VTEs.”
BackgroundPosttransplant maintenance therapy in multiple myeloma: the changing landscape
Sengsayadeth, S. M., Malard, F., Savani, B. N., Garderet, L., & Mohty, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.23 · Cited by 39
Maiese, E. M., Ainsworth, C., Moine, J.-G. L., Ahdesmäki, O., Bell, J. A., & Hawe, E. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.01.014 · Cited by 38
Minakata, D., Fujiwara, S., Yokoyama, D., Noguchi, A., Aoe, S., Oyama, T., Koyama, S., Murahashi, R., Nakashima, H., Hyodo, K., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18654 · Cited by 39
Neri, P. E., Barwick, B. G., Jung, D., Patton, J. C., Maity, R., Tagoug, I., Stein, C. K., Tilmont, R., Leblay, N., Ahn, S., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0061 · Cited by 40
“IMiDs are reported to modulate the immune system, reduce angiogenesis, and cause cytostatic inhibition of MM cells (3); the mechanism underlying these activities was not discovered until after their clinical efficacy was established (4, ).”
BackgroundResultCritically ill cancer patients in the intensive care unit: short‐term outcome and 1‐year mortality
Mokart, D., Etienne, A., Esterni, B., Brun, J. P., Chow‐Chine, L., Sannini, A., Faucher, M., & Blache, J. (2011) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2011.02579.x · Cited by 40
Streiff, M. B. (2013) · PubMed · Cited by 35
Prognostic Effect of Comorbidity Indices in Elderly Patients With Multiple Myeloma
Bila, J., Jelicic, J., Djurasinovic, V., Vuković, V., Sretenović, A., Andjelic, B., Antic, D. A., Todorović, M., & Mihaljević, B. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.03.004 · Cited by 35
Chen, M.-H., Qi, C. X. Y., Saha, M. N., & Chang, H. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcphc85dgaxzdbe · Cited by 37
Advances in therapy of multiple myeloma
Bladé, J., & Rosiñol, L. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283136984 · Cited by 37
Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia
Musto, P., Pietrantuono, G., Guariglia, R., Villani, O., Martorelli, M. C., D’Auria, F., Zonno, A., & Lerose, R. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.03.013 · Cited by 35
Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
Vo, M.-C., Nguyen, T.-A. T., Lee, H., Nguyen-Pham, T.-N., Lakshmi, T. J., Jung, S., Kim, H., & Lee, J. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.11.004 · Cited by 35
Roy, A. L., Prébet, T., Castellano, R., Goubard, A., Riccardi, F., Fauriat, C., Granjeaud, S., Benyamine, A., Castanier, C., Orlanducci, F., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00977 · Cited by 36
“Administration is approved in patients with transfusion-dependent anemia due to low risk myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 5 [del(5q)] (1), for the treatment of multiple myeloma (MM) (2) and for other B cell lymphomas (3, 4).”
BackgroundSimplifying Access to Targeted Protein Degraders via Nickel Electrocatalytic Cross‐Coupling
Neigenfind, P., Massaro, L., Péter, Á., Degnan, A. P., Emmanuel, M. A., Oderinde, M. S., He, C., Peters, D., Ewing, T. E., Kawamata, Y., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202319856 · Cited by 34
Möller, J., Nicklasson, L., & Murthy, A. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.611841 · Cited by 37
“Only direct medical costs were considered since the patients in the Weber et al.11 and Dimopoulos et al.12 studies were above 65-years-old or older, and consequently the indirect cost of lost production was supposed to be minimal.”
BackgroundMethodInfluentialThe evolution and impact of therapy in multiple myeloma
Laubach, J. P., Richardson, P. G. G., & Anderson, K. C. (2010) · Medical Oncology · doi:10.1007/s12032-010-9442-2 · Cited by 40
“Following a very encouraging series of trials in the phase I/II setting [65, 66], the clinical activity of lenalidomide in MM was unequivocally demonstrated in two large phase III trials wherein the combination of lenalidomide and dexamethasone proved superior to dexamethasone alone in patients with relapsed and refra…”
BackgroundPlasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis
Jimenez-Zepeda, V. H., & Domínguez, V. J. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0288-3 · Cited by 35
“Subsequently, on the basis of two large phase III trials, [82, 83], lenalidomide in combination with dexamethasone was approved by the FDA and European Medicines Agency (EMEAS) for the treatment of myeloma patients who had received at least one therapy earlier.”
BackgroundCurrent Therapeutic Strategy for Multiple Myeloma
Suzuki, K. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys215 · Cited by 37
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist
Raza, S., Safyan, R. A., E, E. R. P., Bowman, C. A., & Lentzsch, S. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716680548 · Cited by 40
The cost‐effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective
Hornberger, J. C., Rickert, J., Dhawan, R., Liwing, J., ASCHAN, J., & Löthgren, M. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01526.x · Cited by 37
“The effects of treatment on time to progression and overall survival (OS) were obtained from published reports of the APEX, MM-009, and MM-010 randomized clinical trials.”
BackgroundMethodResultInfluentialDurie, B. G. M. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70008-6 · Cited by 36
Management of myeloma-associated renal dysfunction in the era of novel therapies
Gaballa, M., Laubach, J. P., Schlossman, R. L., Redman, K., Noonan, K., Mitsiades, C. S., Ghobrial, I. M., Munshi, N. C., Anderson, K. C., & Richardson, P. G. G. (2012) · Expert Review of Hematology · doi:10.1586/ehm.11.72 · Cited by 36
Kyle, R. A., & Steensma, D. P. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_1 · Cited by 48
Lenalidomide — The Phoenix Rises
List, A. F. (2007) · New England Journal of Medicine · doi:10.1056/nejme078203 · Cited by 34
Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma
Lonial, S., Kaufman, J. L., Laubach, J. P., & Richardson, P. G. G. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.847919 · Cited by 33
“This is broadly comparable with the incidence of grade 3/4 hematologic toxicities observed in the two pivotal Phase III trials of lenalidomide/high-dose dexamethasone in relapsed/refractory MM, MM-009 and MM-010 [22,23], in which the respective incidence of grade 3/4 neutropenia, thrombocytopenia, anemia, and febrile…”
BackgroundResultInfluentialManagement Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives
Jakubowiak, A. J. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.05.003 · Cited by 35
Pomalidomide therapy for myeloma
Schey, S., & Ramasamy, K. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.567265 · Cited by 34
“This combination is associated with the overall response rates (ORRs) ranging from 43 to 82%, depending on the number and type of prior therapies [20,21].”
BackgroundFaiman, B. M., Mangan, P. A., Spong, J., & Tariman, J. D. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.s1.66-76 · Cited by 41
Andres, M., Feller, A., & Arndt, V. (2018) · Cancer Epidemiology · doi:10.1016/j.canep.2018.01.015 · Cited by 36
Morita, T. O., Yamaguchi, A., Kimura, S., Fujii, H., Endo, K., Izumi, K., Saito, S., & Minami, H. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215593623 · Cited by 32
Chen, N., Weiss, D., Reyes, J. F., Liu, L., Kasserra, C., Wang, X., Zhou, S. Y., Kumar, G. N., Weiss, L., & Palmisano, M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2438-4 · Cited by 32
Lonial, S., & Cavenagh, J. D. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07649.x · Cited by 35
“…the toxicity profiles of these agents differ; the incidences of fatigue, somnolence and PN are substantially lower in lenalidomidetreated patients, but the incidence of haematological toxicities is increased (Bartlett et al, 2004; Richardson et al, 2005; Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundThrombin generation as a predictor of thromboembolic events in multiple myeloma patients
Leiba, M., Malkiel, S., Budnik, I., Rozic, G., Avigdor, A., Duek, A., Nagler, A., Kenet, G., & Livnat, T. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.03.010 · Cited by 32
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
Cook, G., Zweegman, S., Mateos, M., Suzan, F., & Moreau, P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.016 · Cited by 34
Xiao, D., Wang, Y.-J., Hu, X., Kan, W., Zhang, Q., Jiang, X., Zhou, Y., Li, J. X., & Lu, W. P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.035 · Cited by 33
Dima, D., Ullah, F., Mazzoni, S. A., Williams, L. S., Faiman, B. M., Kurkowski, A., Chaulagain, C. P., Raza, S., Samaras, C. J., Valent, J. N., et al. (2023) · Cancers · doi:10.3390/cancers15072160 · Cited by 33
The Development and Pharmacology of Proteasome Inhibitors for the Management and Treatment of Cancer
Ruggeri, B., Miknyoczki, S. J., Dorsey, B. D., & Hui, A. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57003-7 · Cited by 34
Armoiry, X., Fagnani, F., Benboubker, L., Facon, T. T. F., Fermand, J., Hulin, C., Moreau, P., & Aulagner, G. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01153.x · Cited by 33
“Lenalidomide, a leading immunomodulatory compounds (12), was then approved in 2007 after the results of the MM-09 and MM-010 phase III trials (13, 14).”
BackgroundSelf-citationInherited thrombotic thrombocytopenic purpura
Galbusera, M., Noris, M., & Remuzzi, G. (2009) · Haematologica · doi:10.3324/haematol.2008.002493 · Cited by 32
Nazha, A., Cook, R., Vogl, D. T., Mangan, P. A., Gardler, M., Hummel, K., Cunningham, K., Luger, S. M., Porter, D., Schuster, S. J., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.63 · Cited by 36
Lenalidomide enhances the anti‐prostate cancer activity of docetaxel in vitro and in vivo
Henry, J. Y., Lu, L., Adams, M., Meyer, B., Bartlett, J. B., Dalgleish, A. G., & Galustian, C. (2011) · The Prostate · doi:10.1002/pros.21488 · Cited by 32
Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
Patel, U., Mir, M. A., Sivik, J. M., Raheja, D., Pandey, M. K., & Talamo, G. (2015) · Hematology Reports · doi:10.4081/hr.2015.5704 · Cited by 32
Kontodimopoulos, N., Samartzis, A., Papadopoulos, A. A., & Niakas, D. A. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/842867 · Cited by 32
“All statistical analyses were performed with SPSS version 15.0.”
MethodInfluentialTen Years of Improvement in the Management of Multiple Myeloma: 2000-2010
Harousseau, J. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.076 · Cited by 36
Self-citationCosta, F., Vescovini, R., Bolzoni, M., Marchica, V., Storti, P., Toscani, D., Accardi, F., Notarfranchi, L., Palma, B. D., Manferdini, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18085 · Cited by 36
Cavo, M., Terpos, E., Bargay, J., Einsele, H., Cavet, J., Greil, R., & de Wit, E. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1437345 · Cited by 33
Cofano, F., Monticelli, M., Ajello, M., Zenga, F., Marengo, N., Perna, G. D., Altieri, R., Cassoni, P., Bertero, L., Melcarne, A., et al. (2019) · Cancer Control · doi:10.1177/1073274819870549 · Cited by 33
Brown, R. E., Stern, S., Dhanasiri, S., & Schey, S. (2012) · The European Journal of Health Economics · doi:10.1007/s10198-012-0395-6 · Cited by 34
“The model simulated patients by creating individuals with their unique attributes and MM clinical histories taken from the MM-009 and MM-010 LEN/DEX clinical trials [9, 10] comparing LEN/DEX versus DEX in patients with at least one prior therapy from centres in North America, Europe, Australia and Israel.”
MethodPönisch, W., Heyn, S., Beck, J., Wagner, I., Mohren, M., Hoffmann, F. A., Lange, T., Schmalfeld, M., Zehrfeld, T., Schwarzer, A., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12361 · Cited by 32
Barosi, G., Merlini, G., Billio, A., Boccadoro, M., Corradini, P., Marchetti, M., Massaia, M., Tosi, P., Palumbo, A., Cavo, M., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1445-y · Cited by 31
“Lenalidomide–dexamethasone (len/dex) combination therapy Len/dex was compared with high-dose dexamethasone in two RCTs of identical design but different locations [57–59].”
MethodDawson, M. A., Opat, S., Taouk, Y., Donovan, M., Zammit, M., Monaghan, K., Horvath, N., Roberts, A. W., Prince, H. M., Hertzberg, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1022 · Cited by 32
Self-citationFuture agents and treatment directions in multiple myeloma
Ocio, E. M., Mitsiades, C. S., Orlowski, R. Z., & Anderson, K. C. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2014.858595 · Cited by 32
Bladé, J., Rosiñol, L., & de Larrea, C. F. (2015) · Blood · doi:10.1182/blood-2014-10-551531 · Cited by 31
“There is evidence that lenalidomide and glucocorticoids have a synergistic effect with a significant increase in the response rate and on the duration of response of the combination (19, 20) compared with lenalidomide alone (37).”
BackgroundManji, H. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834a94b6 · Cited by 38
Expanding role of lenalidomide in hematologic malignancies
Ghosh, N., Grunwald, M. R., Fasan, O. O., & Bhutani, M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s81310 · Cited by 31
Palumbo, A. P., & Sonneveld, P. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1053866 · Cited by 31
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond
Guirguis, A. A., & Ebert, B. L. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.004 · Cited by 31
Ailawadhi, S., Advani, P. P., Yang, D., Ghosh, R. N., Swaika, A., Roy, V., Foran, J. M., Colón‐Otero, G., & Chanan-Khan, A. A. (2015) · Cancer · doi:10.1002/cncr.29771 · Cited by 30
“In 1971, the National Cancer Act established the Cancer Centers Branch of the National Cancer Institute (NCI) and thereby formalized the establishment of NCI-designated cancer centers (CCs).8 The National Comprehensive Cancer Network (NCCN) represents an alliance of leading CCs that have the objective of improving qua…”
BackgroundInfluentialImmunomodulatory drugs in the treatment of multiple myeloma
Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 33
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Mogollón, P., Díaz-Tejedor, A., Algarín, E. M., Paíno, T., Garayoa, M., & Ocio, E. M. (2019) · Cells · doi:10.3390/cells8111432 · Cited by 32
Alegre, A. M., Oriol, A., García‐Laraña, J., Mateos, M., Sureda, A. M., Martínez‐Chamorro, C., Cibeira, M. T., Aguado, B., Knight, R., & Rosettani, B. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.662643 · Cited by 31
Self-citationAguiar, P. M., Lima, T. D. M., & Storpirtis, S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12384 · Cited by 30
Bone Disease in Multiple Myeloma
Eda, H., Santo, L., Roodman, G. D., & Raje, N. S. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_14 · Cited by 33
“Novel treatments including thalidomide [1], lenalidomide [2], and the proteasome inhibitor bortezomib [3] have led to significant improvements in 5-year relative overall survival, from nearly 28.”
BackgroundKotchetkov, R., Masih‐Khan, E., Chu, C., Atenafu, E. G., Chen, C. I., Kukreti, V., Trudel, S., Tiedemann, R. E., & Reece, D. E. (2016) · Cancer Medicine · doi:10.1002/cam4.799 · Cited by 32
Brayer, J. B., & Baz, R. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717710171 · Cited by 31
Lenalidomide in multiple myeloma: Current status and future potential
Quach, H., Kalff, A., & Spencer, A. G. (2012) · American Journal of Hematology · doi:10.1002/ajh.23234 · Cited by 29
“In the relapse setting, combination len-dex was proven efficacious in two parallel phase III trials, MM-009 [41] and MM-010 [42], which were conducted in United States/Canada, and Europe/Australia/Israel, respectively.”
Self-citation
Metadata
- Authors
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., & Knight, R. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- The Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Peter MacCallum Cancer Centre (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Gdańsk Medical University (PL)
- Hôpital Claude Huriez (FR)
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Celgene (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992538067
- Semantic Scholar
- 32cf6aa2c629905ca550153f79309e6594cf499b
- Cited by
- 1,450
- References
- 17
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 24 · 2023: 55 · 2022: 50 · 2021: 46 · 2020: 59 · 2019: 54 · 2018: 68 · 2017: 87 · 2016: 97 · 2015: 86 · 2014: 90 · 2013: 135 · 2012: 126
- FWCI
- 67.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, thalidomide analogues, time to progression, overall survival, complete response, neutropenia, venous thromboembolism, thrombocytopenia, combination chemotherapy, adverse events, immunomodulators, corticosteroids, treatment efficacy comparison
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.